Insulin-stimulated total glucose disposal was increased by 36% in PCOS patients in response to pioglitazone (P<0.01), and this was partly accounted for by a 26% increase in glucose oxidation (P<0.05) and a 50% increase in non-oxidative glucose metabolism (P<0.01). The gene discussed is INS; the disease is polycystic ovary syndrome.